Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine)
Envelope Glycoprotein E, His, Varicella-zoster Virus (strain Oka Vaccine)

The purity of Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine) is greater than 95% as determined by SEC-HPLC.

Envelope Glycoprotein E, His, Varicella-zoster Virus (strain Oka Vaccine)

Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine) on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine)

VZV glycoprotein E (gE) is most abundantly expressed on the surface of infected cells, and is an essential component for virus replication and cell-to-cell transmission. It is also the main target of virus-specific antibodies and T cell responses that is often selected as vaccine candidate antigen.
Z06450
¥55,963.00

Ask us a question
Product Introduction
Species Varicella-zoster virus (strain Oka vaccine)
Protein Construction
Envelope glycoprotein E (Ser31-Tyr538)
Accession # Q9J3M8		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1 EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 58.39 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-85 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • Envelope Glycoprotein E, His, Varicella-zoster Virus (strain Oka Vaccine)
    • Envelope Glycoprotein E, His, Varicella-zoster Virus (strain Oka Vaccine)

    The purity of Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine) is greater than 95% as determined by SEC-HPLC.

  • Envelope Glycoprotein E, His, Varicella-zoster Virus (strain Oka Vaccine)
    • Envelope Glycoprotein E, His, Varicella-zoster Virus (strain Oka Vaccine)

    Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine) on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background VZV glycoprotein E (gE) is most abundantly expressed on the surface of infected cells, and is an essential component for virus replication and cell-to-cell transmission. It is also the main target of virus-specific antibodies and T cell responses that is often selected as vaccine candidate antigen.
Synonyms Envelope glycoprotein E; gE; ORF68;

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.